Cutter Capital Management, LP Biocryst Pharmaceuticals Inc Transaction History

Cutter Capital Management, LP

  • $0
  • Q2 2025

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$6.41 - $8.69 $7.55 Million - $10.2 Million
-1,177,161 Reduced 59.59%
798,137 $6.07 Billion
Q2 2024

Aug 14, 2024
SELL
$4.13 - $6.79 $537,564 - $883,793
-130,161 Reduced 6.18%
1,975,298 $12.2 Billion
Q1 2024

May 15, 2024
BUY
$4.89 - $7.65 $2.85 Million - $4.46 Million
583,647 Added 38.35%
2,105,459 $10.7 Billion
Q4 2023

Feb 14, 2024
BUY
$4.98 - $6.77 $7.58 Million - $10.3 Million
1,521,812 New
1,521,812 $9.12 Billion

Others Institutions Holding BCRX

# of Institutions
316
Shares Held
199M
Call Options Held
802K
Put Options Held
564K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.55B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Cutter Capital Management, LP Portfolio

Follow Cutter Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutter Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutter Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email